68Ga-PSMA PET/CT Imaging in Assessment of Prostate Cancer

Completed

• Conditions: PET/CT; Prostate Specific Membrane Antigen; IMAGE

• Registration Number: NCT05134064
• Lead Sponsor: RenJi Hospital

Brief Summary

Dual-time point 68Ga-PSMA PET/CT could increase the lesion detection in PCa patients, it remains difficult to perform in clinical practice. The possibility of one-time point 68Ga-PSMA PET/CT imaging could be achieved using a total-body PET/CT.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-12-01
• Primary Completion: 2021-07-31
• Study Completion: 2021-08-31
• Status Verified: 2021-11
• Study First Submitted: 2021-11-03
• Study First Submitted QC: 2021-11-15
• Last Update Submitted: 2021-11-15
• Study First Posted: 2021-11-24
• Last Update Posted: 2021-11-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 66

Inclusion Criteria

• primary staging of pathology-confirmed PCa or evidence of BCR with PSA value > 0.2 ng/ml
• positive 68Ga-PSMA findings
• both standard and delayed scans were performed on the total-body PET/CT

Exclusion Criteria

• only one scan was performed
• negative PSMA results

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Only one-time point scan is possible for PSMA PET/CT	8 months	By the use of total- body PET/CT scanner, the imaging quality between the 1 h p.i. and 3 h p.i. imaging acquisition are compared. And the different lesion detection rates at 3 h p.i. and 1 h p.i. are also discussed. The uptake value differences of all lesions are compared.

Trial Locations

Locations (1)

Shanghai jiaotong University School of Medicine, Renji Hospital; 🇨🇳 Shanghai, Shanghai, China